Novelix Pharmaceuticals Limited (formerly known as trimurthi Limited) has submitted revised unaudited financial results for the quarter ended December 31, 2025, to the BSE. The revision was necessitated due to typographical errors in the auditor's limited review report, with the corrected version submitted on February 14, 2026.

Financial Performance Overview

The company demonstrated robust financial performance during Q3FY26, with significant improvements across key metrics compared to the corresponding quarter of the previous year.

Quarterly and Nine-Month Performance

The company's performance showed consistent improvement on a sequential basis as well. Total income increased from ₹3,639.14 lakhs in Q2FY26 to ₹4,840.27 lakhs in Q3FY26. For the nine months ended December 31, 2025, the company reported total income of ₹10,714.52 lakhs compared to ₹987.35 lakhs in the corresponding nine-month period of the previous year.

Earnings Per Share and Capital Structure

The company's earnings per share (EPS) for continuing operations showed improvement, with basic EPS at ₹0.58 for Q3FY26 compared to ₹0.15 in Q3FY25. The paid-up equity share capital increased to ₹1,721.50 lakhs as of December 31, 2025, from ₹995.00 lakhs in the previous year.

Business Focus and Operations

Novelix Pharmaceuticals operates in a single business segment focused on pharmaceutical research, analysis, manufacturing, and trading of active pharmaceutical ingredients (bulk drugs). The company has discontinued activities in investment in shares, trading in shares, foods, and finance segments to concentrate on its core pharmaceutical operations.

Regulatory Compliance and Approval

The unaudited financial results were reviewed by CVS Balachandra Rao & Co., Chartered Accountants, and received a clean limited review report. The results were reviewed by the Audit Committee and subsequently approved by the Board of Directors at their meeting held on February 12, 2026. The board meeting commenced at 5:00 PM and concluded at 5:30 PM, with the results being made available on the company's website at https://novelixpharma.com .

Novelix Pharmaceuticals Limited (formerly Trimurthi Limited) announced significant corporate developments following its Board meeting held on January 19, 2026. The company successfully allotted 400,000 equity shares upon warrant conversion and made a key management appointment.

Equity Share Allotment Details

The Board approved the allotment of 400,000 equity shares with a face value of ₹10.00 each at an issue price of ₹20.00 per share, including a premium of ₹10.00 per share. These shares were issued upon conversion of warrants by non-promoter category holders who paid the remaining 75% of the issue price, amounting to ₹15.00 per warrant.

Strategic Investor Allocation

Three strategic investors participated in the warrant conversion, with the allocation distributed among non-promoter category investors:

Impact on Share Capital

Following this allotment, the company's paid-up equity capital increased substantially. The capital structure expanded from ₹172.15 crores consisting of 17,215,000 equity shares to ₹176.15 crores comprising 17,615,000 equity shares of ₹10.00 each.

Warrant Conversion Background

These warrants originated from 15,000,000 warrants allotted on January 10, 2025, on a preferential basis. The original allotment followed a special resolution passed by shareholders at an Extra-Ordinary General Meeting held on November 18, 2024, with in-principle approval received from BSE Limited on December 31, 2024. The company noted that 7,265,000 warrants had already been converted previously.

Management Appointment

The Board also approved the appointment of Mr. Gnana Prakash Gattu (DIN: 00517921), Director of the Company, as Nodal Officer under the Investor Education and Protection Fund Authority (Accounting, Audit, Transfer and Refund) Rules, 2016. This appointment ensures compliance with regulatory requirements for investor protection and fund management.

The Board meeting commenced at 5:00 PM at the company's registered office in Hyderabad and concluded at 5:30 PM with a vote of thanks.